Clinical Guidelines

AAO Recap: 3.5-Year Observations from the GATHER2 Open-Label Extension (OLE) Trial

  • By

  • February 26, 2026

  • 2 min

Share

Dr. Arshad Khanani presented the GATHER2 OLE trial results for Avacincaptad Pegol (ACP), aimed at treating geographic atrophy secondary to age-related macular degeneration (AMD), at the AAO in October. The trial indicated a risk of increased neovascular AMD and retinal detachments following intravitreal injections. Important precautions include the potential for endophthalmitis, increased intraocular pressure, and adverse reactions such as conjunctival hemorrhage and blurred vision. Safe administration and patient monitoring are emphasized.

Original Source(s)

AAO Recap: 3.5-Year Observations from the GATHER2 Open-Label Extension (OLE) Trial

  • February 26, 2026

  • 2 min

Related Content

Bridging Pakistan’s Vision Gap

From doorstep to hospital: tackling preventable vision impairment in Pakistan

Military Discipline, Medical Optimism

Sitting Down With… Scott Barnes, Chief Medical Office, STAAR Surgical

When the Visual Cortex Surprises Us 

Clinical trial observes unexpected vision recovery in NAION patient after cortical microstimulation

  • February 25, 2026

  • 4 min